tbuckley/cabot-search huggingface dataset:
Community Demand for Doctors in the next 10 Years
Authors: J. M. Last
Journal: BMJ (1969)

The demand for doctors has increased despite improved community health, because the prevalence of chronic disease has increased, and because affluence, better education, and the growth of specialization have all stimulated demand. Most authorities have recommended an increase in the supply of doctors to meet the increasing demand. Nevertheless, a supply which preserves the present ratio of doctors to population might be adequate if medical productivity were raised. Moreover, an increase of the supply stimulates further demand; perhaps demand would fall if the supply were reduced, and community health might not deteriorate as a result of this. Other social institutions besides medicine have a claim on the available pool of talent from which doctors are recruited. It is possible that medicine already receives its fair share.
Abstract 217: Study II - Antinuclear Antibody Levels Study in Postural Orthostatic Tachycardia Syndrome
Authors: Swathi Solipuram, Fabian Wayar, Apeksha Bhattarai, Chandralekha Ashangari, Amer Suleman
Journal: Circulation Research (2017)

Background: Postural Orthostatic Tachycardia Syndrome (POTS) is a constellation of signs and symptoms that occurs when the patient stands upright. It affects primarily young women. The antinuclear antibody (ANA) test measures the amount and pattern of antibodies in blood that work against own body (autoimmune reaction). If there are more antibodies in the blood than normal, the test is positive. Previously, we have conducted a research on increased ANA levels and POTS and found that 41% of them had positive results. Taking that one step ahead, the aim of this study is to demonstrate further pathologic conditions in patients found to have positive ANA values. Methods: 27 patients who were having positive ANA levels were selected and followed up on with phone calls about their contact with the rheumatologists out of whom 1 patient (4%) declined to participate in the research. Results: Out of 27 patients, 26 patients were Females (age 33.84±12.37) and 1 patient was male (age 24). 11 out of 27(40%) patients reported that they never visited rheumatologists, 15 out of 27 (55%) patients reported rheumatologist visit, 1 out of 27 (3.70%) patient reported endocrinologist visit, 2 out of 27(7.40%) patients reported that their ANA level was monitored by Primary Care Physician. 2(7.40%) patients were diagnosed with Systemic Sclerosis, 2(7.40%) patients were diagnosed with Rheumatoid Arthritis, 3(11.11%) patients were diagnosed with Systemic Lupus Erythematosus. 7 out of 15 patients had other diagnosis; 3(11.11%) patients had Ehlers Danlos Syndrome, 2(7.40%) patients had Osteoarthritis, 1(3.70%) patient had Larsen syndrome, 1(3.70%) patient had Hashimoto’s thyroiditis, 1(3.70%) patient had Fragile X Syndrome, 1(3.70%) patient had Fibromyalgia. Conclusion: 1) 41% of POTS patients had elevated ANA levels. 2) Elevated ANA levels represents a measure of autoimmune mechanism in a subset of POTS patients. 3) Elevated ANA levels incidentally found need to be further studied.
THE EXPERIMENTAL PRODUCTION OF CONGENITAL DEFECTS
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Response
Authors: J. BRISSON, A. S. MORRISON
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Response Get access JACQUES BRISSON, JACQUES BRISSON Epidemiology Unit Department of Social and Preventive Medicine Laval University Quebec CityQc Canada G1K 7P4 Search for other works by this author on: Oxford Academic PubMed Google Scholar ALAN S. MORRISON ALAN S. MORRISON Department of Community Health Brown UniversityProvidence, RI 02912 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 12, 21 June 1989, Page 963, https://doi.org/10.1093/jnci/81.12.963-a Published: 21 June 1989
POLITICS AND PUBLIC HEALTH IN SAN FRANCISCO.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<i>Erratum</i>: Vol. 69, No. 39
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

In the report, "COVID-19 Trends Among School-Aged Children -United States, March 1-September 19, 2020," the percentage of school-aged children with underlying conditions was calculated using school-aged children for whom one or more underlying conditions was reported as the denominator.Information on underlying conditions is not reported for the vast majority (approximately 80%) of school-aged children included in CDC's National Notifiable Diseases Surveillance System, so using the total population as the denominator to calculate the percent of children with underlying conditions would substantially underestimate the prevalence of underlying conditions.To correct this, the percentage of school-aged children with underlying conditions was recalculated using school-aged children for whom underlying condition status was known as the denominator (i.e., a "yes" or "no" on case report form, excluding "unknown" and no information).On page 1410, in the first paragraph, the seventh sentence should have read "Underlying conditions were more common among school-aged children with severe outcomes related to COVID-19: among school-aged children who were hospitalized, admitted to an intensive care unit (ICU), or who died, 23%, 38%, and 33%, respectively, had at least one underlying condition.
Pathology and Morbid Anatomy.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
QLIF-07. HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN PATIENTS WITH PROGRESSIVE GLIOBLASTOMA TREATED WITH COMBINED BEVACIZUMAB AND LOMUSTINE VERSUS LOMUSTINE ONLY (RANDOMIZED PHASE III EORTC STUDY 26101)
Authors: Martin Taphoorn, Andrew Bottomley, Corneel Coens, Jaap Reijneveld, Thierry Gorlia, Alba Ariela Brandes, Julien Domont, Ahmed Idbaih, Martin van den Bent, Wolfgang Wick
Journal: Neuro-Oncology (2016)

Progression-free survival, but not overall survival, was prolonged in the experimental treatment arm with bevacizumab and lomustine (BEV/LOM) compared to the lomustine only control (LOM) arm of randomized EORTC 26101 including patients with recurrent glioblastoma. The aim of this study is to evaluate treatment effects on HRQoL. HRQoL was assessed using the EORTC core questionnaire (QLQ-C30) and brain module (QLQ-BN20). Assessments were performed at baseline, and every 12 weeks during treatment until progression of disease. Preselected scales for analysis were Global Health Status (GHS), Physical Functioning (PF), Social Functioning (SF), Motor Dysfunction (MD) and Communication Deficit (CD). Primary endpoint was HRQoL during the last assessment following baseline until week 36. In addition, Time to HRQoL Deterioration (TTD) and HRQoL Deterioration Free Survival (DFS) were determined. 402/437 patients (92%) had a HRQoL assessment at baseline. Compliance dropped to 66% at week 36, limiting further analysis. At the last assessment, no differences were observed for preselected scales, apart from SF at last assessment being clinically relevant lower in the BEV/LOM arm (mean 66 versus 81, p=0.001). Of note, baseline score for SF was 66 in the BEV/LOM arm and 71 in the LOM arm, showing stable SF for patients in BEV/LOM arm and improved SF for patients in the LOM arm during follow-up. TTD, not including progression as an event, was not different between treatment arms (median 13 weeks versus 13.1 weeks in the BEV/LOM and LOM arm, respectively; p=0.648), in contrast to DFS, with a significantly longer DFS in the BEV/LOM arm (median 12.4 weeks versus 6.7 weeks in the BEV/LOM and LOM arm, respectively; p<0.001), reflecting the difference in time to progression between arms. Addition of bevacizumab to lomustine did not negatively affect HRQoL during the progression-free period.
The significant seventies
Authors: G. D. Dorman
Journal: JAMA (1969)

Today is the last time a President of the AMA will address this House of Delegates in the 1960's. The next time we convene, the world, this nation and our profession will have passed a new decade. This is a good time to reassess ourselves and consider the future challenges and opportunities of the next decade. It seems to me we are in a unique position in our history and that the seventies may be important enough to be dubbed the significant seventies. This is not sentimental optimism. It is based on my contacts this year throughout our country, where I have seen progress in many areas and have met thousands of persons who are concerned about the future of medicine. We who are gathered here this week represent those thousands as we work on the programs, policies, activities, and direction of the medical profession, and its allies. The seventies
What lies ahead for American physicians: one economist's views
Authors: E. Ginzberg
Journal: JAMA (1985)

During the past months, I have participated in several conferences centered around the changing structure of the US health care system and what these changes hold in store for physicians. I listened with a third ear to the questions raised by physicians in the audience, both the older, established members and the younger people who were just getting established. Occasionally residents and medical students also participated. One and all, these physicians gave evidence of concern, unease, confusion, discontent, and anxiety about what was happening and, more particularly, what would happen to their profession and to themselves and their colleagues. As a long-term student of physician personnel and the economics of the health care system, here are my best "hunches." Any attempt to attach a more respectable term to the uncertain future would be presumptuous. But in the absence of anything better, even hunches may be of some use, especially since
Phase II Trial of Carboplatin and Pemetrexed as First-Line Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer and Correlation between the Efficacy/Toxicity and Single Nucleotide Polymorphisms Associated with Pemetrexed Metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902
Authors: K. Kanazawa, T. Ishida, Y. Fujita, S. Fujiuchi, T. Harada, M. Harada, K. Takamura, I. Kinoshita, Y. Katsuura, O. Honjo, T. Kojima, S. Oizumi, H. Isobe, M. Munakata, M. Nishimura
Journal: Annals of Oncology (2012)
RECLAMATION OF THE PHYSICALLY HANDICAPPED
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Populations Receiving Optimally Fluoridated Public Drinking Water—United States, 1992-2006
Journal: JAMA (2008)

Water fluoridation has been identified by CDC as one of 10 great public health achievements of the 20th century. The decline in the prevalence and severity of dental caries (tooth decay) in the United States during the past 60 years has been attributed largely to the increased use of fluoride. Community water fluoridation is an equitable and cost-effective method for delivering fluoride to the community. A Healthy People 2010 objective is to increase to 75% the proportion of the U.S. population served by community water systems who receive optimally fluoridated water. To update and revise previous reports on fluoridation in the United States and describe progress toward the Healthy People 2010 objective, CDC analyzed fluoridation data for the period 1992-2006 from the 50 states and District of Columbia (DC). The results indicated that the percentage of the U.S. population served by community water systems who received optimally fluoridated water increased from 62.1% in 1992, to 65.0% in 2000, and 69.2% in 2006, and those percentages varied substantially by state. Public health officials and policymakers in states with lower percentages of residents receiving optimal water fluoridation should consider increasing their efforts to promote fluoridation of community water systems to prevent dental caries.
Evaluation of the Present Status of DDT With Respect to Man
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Outbreak of Acute Gastroenteritis Attributable to Escherichia coli Serotype O104:H21— Helena, Montana, 1994
Journal: JAMA (1995)

During February-March, 1994, four persons in Helena, Montana (1995 population: 24,569), developed bloody diarrhea and severe abdominal cramps. Stool cultures for Salmonella, Shigella, Campylobacter, and Escherichia coli O157:H7 were negative; however, sorbitol-negative E. coli colonies were identified in stools from all four patients. Isolates from three patients were identified at CDC as a rare serotype--E. coli O104:H21 that produced Shiga-like toxin II. This report summarizes the epidemiologic and laboratory investigations of this outbreak by the Lewis and Clark County Department of Health and Environmental Sciences, the Montana Department of Health and Environmental Sciences (MDHES), and CDC.
Mental Capacity, Legal Competence and Consent to Treatment
Authors: Alec Buchanan
Journal: Journal of the Royal Society of Medicine (2004)

Deciding whether someone is legally competent to make decisions regarding their own treatment requires an assessment of their mental capacity. The assessed capacity required for legal competence increases with the seriousness of what is at stake. The usual explanation is that patient autonomy is being balanced against best interests. An alternative explanation, that we require greater room for error when the consequences are serious, implies a change to clinical practice and in the evidence doctors offer in court.
Respiratory Medicine
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A SIMPLE AND INEXPENSIVE APPARATUS FOR DIAGNOSTIC OR THERAPEUTIC PUNCTURES
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Parallel 11: Hepatitis C: Health Economics and Cost-Effectiveness
Authors: Mary Pauly, Lue-Yen Tucker, Jean-Luc Szpa- Kowski, David Baer, Joanna Ready, Jessica Hwang, Vinod Rustgi -Grant, Alexis Chidi, Shari Rogal, Cindy Bryce, Michael Fine, Chester Good, Larissa Myaskovsky, Allan Tsung, Kenneth Smith, Adriaan Van Der Meer, Raoel Maan, Jordan Feld, Heiner Wedemeyer, Giovanna Fattovich, Jean-Francois Dufour, Frank Lammert, Andres Duarte-Rojo, Michael Manns, Ste- Fan Zeuzem, Wolf Hofmann, Donatella Ieluzzi, Robert De Knegt, Bettina Hansen, Bart Veldt, Harry Janssen
Journal: Hepatology (2014)

233Ain 247 (2.8%) patients, including 3 (13%) HBsAg+, 12 (3%) HBsAg-/anti-HBc+, 112 (3%) HBsAg-/anti-HBc-, and 30 (1%) never tested group.HT ≥3 was attributed to HBV reactivation in 3 patients including 2 with baseline HBsAg+, 50 with other causes of liver injury, and in the remaining patients the cause was unclear.Antiviral prophylaxis was started in 5 HBsAg+ patients prior to anti-TNF.Conclusions: In this large cohort of patients receiving anti-TNF, roughly half were tested for HBV prior to initiation of therapy.Reactivation of HBV occurred in 17% of HBsAg+ pts.A few cases of HT>3 were attributed to HBV reactivation but the cause of HT>3 was unclear in most cases.
Oncology Research Program
Authors: Stacy Moulder, Senthil Damodaran, Elizabeth Mittendorf, W Symmans
Journal: Journal of the National Comprehensive Cancer Network (2017)

The goal of the Highlights of the NCCN Oncology Research Program (ORP) is to provide readers with more information on the ORP, including studies currently accruing patients.For more information on specific trials, including patient selection criteria, please use the contact information listed with each study.